口腔がん治療の世界市場-2023年～2030年

市場概要

口腔がん治療の世界市場は、2022年に21億2,000万米ドルに達し、2030年には32億米ドルに達するなど、有利な成長が予測されています。世界の口腔がん治療市場は、予測期間中（2023～2030年）に6.1%のCAGRを示すと予測されています。個別化医療への注目の高まり、免疫療法の台頭、放射線療法の技術進歩などが最近の市場動向です。

世界の口腔がん治療市場は近年継続的に拡大しています。口腔がんは、口唇、舌、頬、口腔底、咽頭を含む口腔における悪性細胞の制御不能な増殖と定義されます。

口腔がん治療の世界市場の範囲は、扁平上皮がん、疣状がん、小唾液腺がん、リンパ腫、その他口腔がん治療市場シェアの使用量を増加させているがん種を包含する構成要素で構成されています。口腔がん治療の世界市場は、口腔がんの有病率の増加、口腔がんに対する認識向上への取り組み、早期発見スキームなどの要因により拡大しています。

市場力学

高齢化人口の増加が口腔がん治療市場の成長を牽引

高齢化社会は、口腔がんを含む様々な健康問題に罹患しやすくなります。高齢化に伴い、口腔扁平上皮がん（OSCC）の高齢患者も増加しています。WHOの2023年改訂推計によると、2020年には377,713人の口唇・口腔がん患者が新たに発生すると予想されています。口腔がんは男性と高齢者に多いです。全体として、高齢者の口腔がん患者数は増加しており、口腔がん治療の需要を押し上げると予測されています。

これは老人人口の増加によるもので、例えば世界保健機関（WHO）の2022年報告によると、2030年までに地球上の約6人に1人が60歳以上になると推測されます。この期間内に、60歳以上の世界人口に占める割合は、2020年の10億人から14億人に増加すると予想されています。

認知度の向上と早期発見プログラムが世界の口腔がん治療市場の主な促進要因

口腔がんに対する意識の高まりと早期発見の必要性から、検診プログラムの実施や啓発キャンペーンが行われています。これらの活動は、口腔がん症例の早期発見を助け、タイムリーな介入と治療結果の改善をもたらします。

例えば、2023年1月24日、ムンバイで開催された年次IHWサミット＆アワードで、Biocon LimitedのCSR部門であるBiocon Foundationが「口腔がん検診プログラム」で表彰されました。インディア・ヘルス・アンド・ウェルネス（IHW）評議会は、このプログラムに「年間最優秀疾病スクリーニング・イニシアチブ」の栄誉ある金賞を授与しました。このように、口腔がんに対する意識の高まりが、予測期間中の市場を牽引すると思われます。

治療の副作用が市場の成長を妨げます

放射線療法や化学療法などの口腔がん治療技術は、粘膜炎、口腔乾燥、嚥下障害などの副作用を引き起こす可能性があります。これらの副作用は患者のQOLに影響を及ぼし、支持療法が必要になることもあります。放射線誘発性粘膜炎は、放射線を受けた頭頸部がん患者の最大91％に影響します。これらの要因を考慮すると、治療に伴う副作用は口腔がん治療市場の成長を制限する可能性があります。

COVID-19影響分析

COVID-19のパンデミックと世界各国での封鎖により、あらゆる業種の企業の財務の健全性が影響を受けています。そのため、COVID-19公衆衛生緊急事態の期間中、米国食品医薬品局（FDA）は、スポンサーと研究者を支援し、試験参加者の安全を確保し、適正臨床実施基準（GCP）を遵守し、試験の完全性に対するリスクを最小限に抑えるための一般的な考慮事項を含むガイドラインを発表しました。

ロシア・ウクライナ紛争の影響分析

ロシア・ウクライナ紛争は、経口がん治療の世界市場に大きな影響を与えています。ヘルスケアインフラを破壊し、被災地での治療アクセスを妨げ、経済的不安定を引き起こし、国際協力を混乱させ、市場力学を変化させました。

損壊したヘルスケア施設、移動の制限、経済的制約、診断の遅れ、研究開発活動の阻害などは、紛争の余波のひとつです。これらの要因は、口腔がん治療の利用可能性と質に総合的に影響し、戦争がヘルスケアシステムと患者の転帰に広範囲に影響を及ぼすことを示しています。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

• 影響要因
  • 促進要因
    • 口腔がんの有病率の増加
    • 治療の進歩
  • 抑制要因
    • 高い治療費
  • 機会
    • 意識の高まりと早期発見プログラム
  • 影響分析

第5章 産業分析

• ポーターの5フォース分析
• サプライチェーン分析
• 価格分析
• 規制分析

第6章 COVID-19分析

第7章 タイプ別

• 扁平上皮がん
• 疣状がん
• 小唾液腺がん
• リンパ腫
• その他

第8章 治療法別

• 標的療法
• 化学療法
• 免疫療法

第9章 流通チャネル別

• 病院薬局
• 小売薬局
• オンライン薬局

第10章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • スペイン
  • イタリア
  • その他欧州
• 南米
  • ブラジル
  • アルゼンチン
  • その他南米
• アジア太平洋
  • 中国
  • インド
  • 日本
  • オーストラリア
  • その他アジア太平洋地域
• 中東・アフリカ

第11章 競合情勢

• 競合シナリオ
• 市況/シェア分析
• M&A分析

第12章 企業プロファイル

• Novartis AG
  • 会社概要
  • 製品ポートフォリオと説明
  • 財務概要
  • 主な発展
• Hospira, Inc.
• Teva Pharmaceutical Industries Ltd
• Pfizer Inc.
• Lilly USA, LLC
• Merck & Co., Inc.
• Fresenius Kabi AG
• Accord BioPharma,Inc.
• Bristol-Myers Squibb Company
• Spectrum Pharmaceuticals, Inc.

第13章 付録

Market Overview

The Global Oral Cancer Treatment Market reached US$ 2.12 billion in 2022 and is projected to witness lucrative growth by reaching up to US$ 3.2 billion by 2030. The global oral cancer treatment market is expected to exhibit a CAGR of 6.1% during the forecast period (2023-2030). The increasing focus on personalized medicine, the rise of immunotherapy, and technological advancements in radiation therapy are some recent market trends.

The global oral cancer treatment market has been expanding continuously in recent years. Oral cancer is defined as the uncontrolled proliferation of malignant cells in the oral cavity, which includes the lips, tongue, cheeks, floor of the mouth, and throat.

The global oral cancer treatment market scope comprises components encompassing cancer types such as squamous cell carcinoma, verrucous carcinoma, minor salivary gland carcinomas, lymphomas, and others which have increased usage of oral cancer treatment market share. The global market for oral cancer treatment is expanding as a result of factors including the increasing prevalence of oral cancer, growing oral cancer awareness initiatives and early detection schemes.

Market Dynamics

Growing Aging Population to Drive the Growth of the Oral Cancer Treatment Market

The aging population is more susceptible to a variety of health problems, including oral cancer. With an aging population, there are more older patients with oral squamous cell carcinoma (OSCC). In 2020, there are expected to be 377,713 new cases of cancer of the lip and oral cavity, according to WHO 2023 revised estimates. Oral cancer is more common in men and older persons. Overall, the number of older people with mouth cancer is increasing, which is predicted to boost the demand for oral cancer treatment.

This is due to the growing geriatric population, for instance, according to World Health Organization (WHO) 2022 report, by 2030, about one out of every six people on the planet will be 60 or older. Within this time span, the share of the world population aged 60 and up is expected to increase from 1 billion in 2020 to 1.4 billion.

Increasing Awareness and Early Detection Programs is the Major Driver in the Global Oral Cancer Treatment Market

The growing awareness of oral cancer and the need for early identification has resulted in the implementation of screening programs and awareness campaigns. These activities aid in the early detection of oral cancer cases, resulting in timely intervention and improved treatment outcomes.

For instance, on 24 january 2023, Biocon Foundation, Biocon Limited's CSR branch, was recognized for its 'Oral Cancer Screening Programme' at the annual IHW Summit & Awards in Mumbai. The India Health and Wellness (IHW) Council awarded the program the prestigious Gold Award in the area of "Disease Screening Initiative of the Year. Thus, increasing awareness about the oral cancer will drive the market over the forecast period.

The Side Effects of Treatment will Hamper the Growth of the Market.

Oral cancer treatment techniques such as radiation therapy and chemotherapy, may cause side effects such as mucositis, xerostomia, and dysphagia. These side effects have an influence on patients' quality of life and may necessitate supportive care treatments. Radiation-induced mucositis affects up to 91% of patients with head and neck cancer who get radiation. Considering these factors, the side effects associated with treatment can limit the oral cancer treatment market growth.

COVID-19 Impact Analysis

The financial health of companies across all industries has been impacted by the COVID-19 pandemic and lockdown in numerous nations throughout the world. Therefore, for the period of the COVID-19 public health emergency, the U.S. Food and Drug Administration (FDA) issued guidelines that include general considerations to aid sponsors and researchers, ensuring the safety of trial participants, adhering to good clinical practice (GCP), and minimizing risks to trial integrity.

Russia-Ukraine War Impact Analysis

The Russia-Ukraine conflict has had significant impacts on the global market for oral cancer treatment. It has disrupted healthcare infrastructure, hampered treatment access in afflicted areas, caused economic instability, disrupted international cooperation, and altered market dynamics.

Damaged healthcare facilities, restricted mobility, financial constraints, delayed diagnosis, and hampered research and development activities are among the repercussions of the conflict. These factors affect the availability and quality of oral cancer therapy collectively, illustrating the war's far-reaching repercussions for healthcare systems and patient outcomes.

Segment Analysis

The global oral cancer treatment market is segmented based on type, treatment, distribution channel, and region.

The Squamous Cell Carcinoma Segment Accounts for 31.2% of Market Share Owing to Rising Prevalence.

The Squamous Cell Carcinoma (SCC) segment is poised to dominate the global oral cancer treatment market due to its high prevalence and well-established treatment approaches. SCC, the most common kind of oral cancer, receives major research and development attention, resulting in breakthroughs in detection and treatment options.

Squamous cell carcinoma (SCC) is a type of cancer that begins in the squamous cells. These are the skin-like flat cells that line the insides of the mouth, nose, larynx, and throat. Cancer is referred to as a carcinoma. SCC accounts for more than 90 percent of all mouth and oropharyngeal cancers. However, there is rising concern about the development of resistance to present oral squamous cell carcinoma (OSCC) treatment options. As a result, there is an urgent need for novel, effective treatments to address this issue and enhance patient outcomes in OSCC.

For instance, scientists from Tokyo Medical and Dental University (TMDU) discovered a remarkable discovery in Molecular Therapy Oncolytics in 2022. They found that miR-634 could significantly reduce cisplatin resistance in oral squamous cell carcinoma (OSCC) cells, resulting in increased tumor cell eradication. When an ointment containing miR-634 was put topically on mice, the outcomes were equivalent. This shows that this simple topical treatment may improve the prognosis of people with advanced oral cancer. Thus driving the segment growth over the forecast period.

Geographical Analysis

North America Accounted for Approximately 36.4% of the Market Share Owing to the Increasing Prevalence of Oral Cancer

North America is expected to dominate the global oral cancer treatment market due to the increasing prevalence of oral cancer in the region. The prevalence of risk factors is increasing, which is a result of variables like lifestyle choices. The sophisticated healthcare system in North America, which includes specialized cancer treatment facilities, knowledgeable medical staff, and a focus on research and development, permits accurate cancer diagnosis and treatment.

For instance, according to American Society of Clinical Oncology (ASCO) report of 2023, in the United States, about 54,540 persons are expected to be diagnosed with oral or oropharyngeal cancer, with men accounting for 39,290 cases and women accounting for 15,250 cases in 2023. The number of people diagnosed with oral or oropharyngeal cancer worldwide in 2020 is expected to reach 476,125. Notably, men had more than double the incidence rates of these malignancies as women, indicating a major gender discrepancy in the frequency of these diseases.

Competitive Landscape

The major global players in the oral cancer treatment market include: Novartis AG, Hospira, Inc., Teva Pharmaceutical Industries Ltd, Pfizer Inc., Lilly USA, LLC, Merck & Co., Inc., Fresenius Kabi AG, Accord BioPharma, Inc. Bristol-Myers Squibb Company, and Spectrum Pharmaceuticals, Inc., among others.

Why Purchase the Report?

• To visualize the global oral cancer treatment market segmentation based on type, treatment, distribution channel, and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of oral cancer treatment market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping is available in Excel consisting of key products of all the major players.

The global oral cancer treatment market report would provide approximately 53 tables, 54 figures and 195 Pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Type
• 3.2. Snippet by Treatment
• 3.3. Snippet by Distribution Channel
• 3.4. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Increasing Prevalence of Oral Cancer
    • 4.1.1.2. Advancements in Treatment
  • 4.1.2. Restraints
    • 4.1.2.1. High Cost of Treatment
  • 4.1.3. Opportunity
    • 4.1.3.1. Rising Awareness and Early Detection Programs
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's 5 Forces Analysis
• 5.2. Supply Chain Analysis
• 5.3. Pricing Analysis
• 5.4. Regulatory Analysis

6. COVID-19 Analysis

• 6.1. Analysis of COVID-19
  • 6.1.1. Scenario Before COVID-19
  • 6.1.2. Scenario During COVID-19
  • 6.1.3. Scenario Post COVID-19
• 6.2. Pricing Dynamics Amid COVID-19
• 6.3. Demand-Supply Spectrum
• 6.4. Government Initiatives Related to the Market During Pandemic
• 6.5. Manufacturers Strategic Initiatives
• 6.6. Conclusion

7. By Type

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 7.1.2. Market Attractiveness Index, By Type
• 7.2. Squamous Cell Carcinoma*
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 7.3. Verrucous Carcinoma
• 7.4. Minor Salivary Gland Carcinomas
• 7.5. Lymphomas
• 7.6. Others

8. By Treatment

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
  • 8.1.2. Market Attractiveness Index, By Treatment
• 8.2. Targeted Therapy*
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 8.3. Chemotherapy
• 8.4. Immunotherapy

9. By Distribution Channel

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 9.1.2. Market Attractiveness Index, By Distribution Channel
• 9.2. Hospitals Pharmacies*
  • 9.2.1. Introduction
  • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 9.3. Retail Pharmacies
• 9.4. Online Pharmacies

10. By Region

• 10.1. Introduction
  • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 10.1.2. Market Attractiveness Index, By Region
• 10.2. North America
  • 10.2.1. Introduction
  • 10.2.2. Key Region-Specific Dynamics
  • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
  • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.2.6.1. The U.S.
    • 10.2.6.2. Canada
    • 10.2.6.3. Mexico
• 10.3. Europe
  • 10.3.1. Introduction
  • 10.3.2. Key Region-Specific Dynamics
  • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
  • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.3.6.1. Germany
    • 10.3.6.2. The U.K.
    • 10.3.6.3. France
    • 10.3.6.4. Spain
    • 10.3.6.5. Italy
    • 10.3.6.6. Rest of Europe
• 10.4. South America
  • 10.4.1. Introduction
  • 10.4.2. Key Region-Specific Dynamics
  • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
  • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.4.6.1. Brazil
    • 10.4.6.2. Argentina
    • 10.4.6.3. Rest of South America
• 10.5. Asia-Pacific
  • 10.5.1. Introduction
  • 10.5.2. Key Region-Specific Dynamics
  • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
  • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.5.6.1. China
    • 10.5.6.2. India
    • 10.5.6.3. Japan
    • 10.5.6.4. Australia
    • 10.5.6.5. Rest of Asia-Pacific
• 10.6. Middle East and Africa
  • 10.6.1. Introduction
  • 10.6.2. Key Region-Specific Dynamics
  • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
  • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

11. Competitive Landscape

• 11.1. Competitive Scenario
• 11.2. Market Positioning/Share Analysis
• 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

• 12.1. Novartis AG*
  • 12.1.1. Company Overview
  • 12.1.2. Product Portfolio and Description
  • 12.1.3. Financial Overview
  • 12.1.4. Key Developments
• 12.2. Hospira, Inc.
• 12.3. Teva Pharmaceutical Industries Ltd
• 12.4. Pfizer Inc.
• 12.5. Lilly USA, LLC
• 12.6. Merck & Co., Inc.
• 12.7. Fresenius Kabi AG
• 12.8. Accord BioPharma,Inc.
• 12.9. Bristol-Myers Squibb Company
• 12.10. Spectrum Pharmaceuticals, Inc.

LIST NOT EXHAUSTIVE

13. Appendix

• 13.1. About Us and Services
• 13.2. Contact Us